FAQ on Calidi Biotherapeutics Inc.'s 1-for-12 Reverse Stock Split

What is a reverse stock split and how does it work?

A reverse stock split reduces the number of shares outstanding by combining multiple shares into one. In this case, every 12 pre-split shares of Calidi Biotherapeutics will convert into one post-split share, with fractional shares rounded up to the nearest whole share.

Why is Calidi Biotherapeutics implementing a reverse stock split?

The reverse stock split is intended to optimize market dynamics, expand investor appeal, and align trading conditions with shareholder interests, as approved by shareholders and ratified by the board.

When will the reverse stock split take effect?

The reverse stock split will take effect on August 5, 2025, with shares beginning to trade on a split-adjusted basis on the NYSE American under the existing ticker ‘CLDI’.

How will the reverse stock split affect shareholders?

Shareholders will see their shares consolidated at a ratio of 1-for-12, with fractional shares rounded up. The split will also proportionately adjust outstanding options, warrants, and equity plan shares.

Will the reverse stock split affect the par value or the number of authorized shares?

No, the reverse stock split will not affect the par value or the number of authorized shares of Calidi Biotherapeutics.

Where can I find more information about Calidi Biotherapeutics?

More information about Calidi Biotherapeutics can be found on their website at www.calidibio.com or in the company’s newsroom at https://ibn.fm/CLDI.

What is Calidi Biotherapeutics’ focus?

Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted genetic medicine delivery platforms to arm the immune system to fight cancer, utilizing novel stem cell-based platforms for oncology indications.

How can I view the full press release about the reverse stock split?

The full press release can be viewed at https://ibn.fm/qFW3H.